A clinical trial of Amplivant – an adjuvant technology to boost immune response to cancer therapy –has started. ISA Pharmaceuticals’ novel technology is being tested in a multicentre clinical trial which is also testing the Moditop vaccine, Modi-1.
The first-in-human clinical trial brings Modi-1 to patients with triple negative breast cancer, ovarian cancer, head and neck cancer and renal cancer using the Amplivant adjuvant technology to boost immune response to the therapy.